Moody's gave a warning to Spain and the Greeks rioted again. CPI showed tame inflation and industrial capacity was close to two-year highs. We also had at least four IPOs and the Senate passed the Bush tax-cut extension for two years. The markets looked set for a rally but the end of day trading again failed to materialize into a win for the bulls. Here were today's closing bell levels:

DJIA: 11,457.47, -19.07 (0.17%)
S&P 500: 1.235.23, -6.36 (0.51%)
NASDAQ: 2,617.22, -10.50 (0.40%)

Top Analyst Upgrades & Downgrades

Option traders appear to be setting up for a bullish move on Cypress Bioscience, Inc. (CYPB). Traders plowed into 1,305 new call option contracts -- 19.19 times the average volume -- on the stock on Friday. And we know that traders were eager to get into this trade because 100% of the trades came in on the ask price.

Cypress has been in a downtrend since hitting a high around $10.00 in July 2009. The stock closed Friday at $3.39, down 10.79% during the past month.

It appears that the Chinese yuan, drug makers and investment banks caught the attention of traders Tuesday -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot today.

Analyst Upgrades

• Kaufman Bros. upgraded Yahoo! (YHOO) to buy from hold after channel checks indicated display advertising is seeing continued improvement in pricing and demand. The firm finds the risk/reward profile on Yahoo! shares attractive at current levels and raised its price target on the stock to $20 from $19.
• Citigroup upgraded Edwards Lifesciences (EW) to buy from hold following the company's investor meeting as it believes new product launches will serve as catalysts in 2010. Citi raised its target on shares to $101 from $72.
• Deutsche Bank upgraded BWAY Holding (BWY) to buy from hold following the company's Q4 results and raised its target on shares to $22 from $17.
• Clearwire (CLWR) was upgraded to buy from sell at Soleil.
• Nokia (NOK) was raised to hold from sell at Societe Generale.
• NCR Corp. (NCR) was upgraded at JPMorgan to overweight from neutral.

Analyst upgrades:

• Ericsson (NASDAQ: ERIC) was upgraded to Add from Hold at WestLB.
  
• JP Morgan upgraded Shire Plc (NASDAQ: SHPGY) to overweight from Neutral to reflect Vyvanse share gains and valuation.
  
• Wachovia upgraded Jefferies (NYSE: JEF) to Market Perform from Underperform because they believe that the recent collapse of the large cap bank sector, Jefferies' cash equity business, and the company's partial privatization as a result of its Leucadia investment will shield shares.
  
• Canaccord upgraded Amylin Pharma (NASDAQ: AMLN) to Hold from Sell.
• ADC Telecomm (NASDAQ: ADCT) was upgraded to Buy from Hold at Kaufman Bros. on valuation following the recent weakness.
• STEC Inc (NASDAQ: STEC) and Popular (NASDAQ: BPOP) were raised to Buy from Neutral at B. Riley.
  

Analyst downgrades:

• Merrill downgraded Disney (NYSE: DIS) to Underperform from Neutral and cut its target to $27 from $34 citing the impact from the current economic climate on earnings.
  
• Barclays downgraded IBM (NYSE: IBM) to Equal Weight from Overweight citing the impact from the weakening economy and the company's large exposure to the financial services industry. IBM's target was cut to $108 from $130.
  
• Jefferies downgraded Salesforce.com (NYSE: CRM) to Underperform from Buy on increased risks of deteriorating payment terms and price pressure on renewals. The company's target was lowered to $36 from $75.
• Goldman downgraded First Solar (NASDAQ: FSLR) and added shares to the Conviction Sell List.

MOST NOTEWORTHY: Cypress Bioscience, Banc of America, Insulet, Taleo and Vocus Inc were today's noteworthy initiations:

• Friedman Billings started shares of Cypress Biosciences Inc (NASDAQ: CYPB) with an Outperform rating and $22 target, and is positive on the company's lead product milnacipran, in Phase III studies for fibromyalgia. The firm expects a 1Q09 launch and believes the U.S. market could be as large as $7B.
  
• Goldman resumed coverage of Bank of America Corporation (NYSE: BAC) with a Buy rating and $63 target as they believe the company has around $22.5B of unrealized gains in its strategic investment portfolio. Goldman also added BAC to their Americas Buy List.
  
• Insulet Corporation (NASDAQ: PODD) was initiated at William Blair with an Outperform rating. The firm believes the unique features of the OmniPod will allow PODD to capture a meaningful portion of the 300,000 current insulin pumpers in the United States.
  
• Soleil started shares of Taleo Corporation (NASDAQ: TLEO) with a Buy rating and $35 target and believes the company's recent growth pace can continue.
  
• Shares of Vocus Inc (NASDAQ: VOCS) were also initiated at Soleil with a Buy rating and $39 target. The firm believes the company can gain share in the early stage market for public relations software given its on-demand model and low price entry point.

OTHER INITIATIONS:

• Cowen initiated shares of Lions Gate Entertainment Corp (NYSE: LGF) and Marvel Entertainment Inc (NYSE: MVL) with an Outperform rating and shares of Dreamworks Animation SKG Inc (NYSE: DWA) with a Neutral rating.
  
• Goldman resumed coverage of Nintendo Co Ltd (OTC: NTDOY) with a Buy rating.

MOST NOTEWORTHY: Aerospace stocks, WuXi Pharma, Myriad Genetics, Cypress Bioscience and Knology were today's noteworthy initiations:

• LYON initiated shares of aerospace stocks including Goodrich Corporation (NYSE: GR), TransDigm Group Inc (NYSE: TDG) and Triumph Group Incorporated (NYSE: TGI) with Add ratings and a $74 target, $45 target and $90 target, respectively.
  
• WuXi Pharmatech (NYSE: WX) was started with a Hold rating and $29 target at Jefferies on valuation. JP Morgan started shares with a Neutral rating and Credit Suisse initiated shares with an Outperform rating.
  
• Myriad Genetics Inc (NASDAQ: MYGN) was started with a Hold rating and $50 target at Citigroup, as the firm is cautious on the Phase III Flurizan results and does not recommend putting new money here at these levels.
  
• Citigroup also initiated shares of Cypress Biosciences Inc (NASDAQ: CYPB) with a Buy rating and $22 target as the firm believes Milnacipran has sufficient database for approval and is capable of gaining meaningful market share as firstline therapy.
  
• Knology Inc (NASDAQ: KNOL) was initiated with a Buy rating and $25 target at BWS Financial, as the firm believes the company's growth potential is greater than other cable companies through a business plan that allows it to have operations in all regions of the U.S.

OTHER INITIATIONS:

• Wachovia resumed coverage of Liberty Media Corporation (NASDAQ: LCAPA) with an Outperform rating.
  
• Northwest Airlines Corporation (NYSE: NWA) and Delta Air Lines Inc (NYSE: DAL) were initiated with Overweight ratings at JP Morgan.
  
• Thomas Weisel started shares of Tyco Electronics (NYSE: TEL) with a Market Weight rating.
  
• Goldman initiated shares of Electronic Arts Inc (NASDAQ: ERTS) and Activision Inc (NASDAQ: ATVI) with Buy ratings and THQ Inc (NASDAQ: THQI) with a Neutral rating.

MOST NOTEWORTHY: Staples, Inc (SPLS), Sun Microsystems, Inc (SUNW), Forest Laboratories, Inc (FRX), AvalonBay Communities (AVB) and ConocoPhillips (COP) were today's noteworthy upgrades:

• Soleil upgraded shares of Staples, Inc (NASDAQ: SPLS) to Buy from Hold following the in-line Q1 results, as the firm believes management's initiatives will benefit the company for the remainder of the year.

• Matrix upgraded Sun Microsystems (NASDAQ: SUNW) to Hold from Sell based on improved profitability and margins due to cost cuts.

• First Albany upgraded Forest Laboratories (NYSE: FRX) to Strong Buy from Neutral following positive preliminary results for Milnacipran in Fibromyalgia.

• AvalonBay Communities (NYSE: AVB) was raised to Market Perform from Underperform at BMO Capital based on valuation.

• Bernstein upgraded shares of ConocoPhillips (NYSE: COP) to Outperform from Market Perform...

OTHER UPGRADES:

• Piper Jaffray upgraded Medtronic, Inc (NYSE: MDT) to Outperform from Market Perform.

• Advanced Analogic Technologies Incorp (NASDAQ: AATI) was upgraded to Buy from Hold at Needham.

• CIBC raised Cypress Bioscience, Inc's (NASDAQ: CYPB) rating to Sector Outperformer from Sector Performer.

• HSBC upgraded Agnico-Eagle Mines Ltd (NYSE: AEM) and AngloGold Ashanti Ltd (NYSE: AU) to Overweight from Neutral.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Cypress Bioscience Inc. (NASDAQ: CYPB) option implied volatility above 200 suggests Risk into Data.
CYPB closed at $7.66. Data from CYPB's end PII Milnacipran (Fibromyalgia Syndrome: FMS) trail, is expected to be released before mid-year. CYPB June option implied volatility is above 200 according to Track Data, suggesting large price fluctuation risk.

South West Energy Co. (NYSE: SWN) implied volatility suggests less Risk as SWN at record High.
SWN, an energy company focused on natural gas, closed at $44.35. SWN has a market cap of $7.5 billion with long term debt of $136 million. SWN reported 2006 annual revenue of $763 million. SWN is expected report EPS on 5/1. SWN May option implied of 38 below its 26-week average of 46 according to Track Data, suggesting decreasing price risks.

Daily Option Update is provided by Stock Options Specialist Paul Foster of theflyonthewall.com.

The Volatility Index for S&P 500 Options (VIX) is up .16 to 13.62.

Cypress Bioscience (NASDAQ: CYPB) -- option implied volatility Elevated at 194. CYPB closed at $7.46. Data from CYPB's end PII Milnacipran (Fibromyalgia Syndrome; FMS) trail, is expected to be released before mid-year. JEFF has a Buy on Attractive Risk/Reward with a $14 price target on CYPB. JEFF says "our diligence with investigators and statisticians increase our confidence in the prospects for a positive outcome." CYPB June option implied volatility is at 194 according to Track Data, suggesting large price fluctuation risk.

Starwood (NASDAQ: HOT) -- implied volatility suggests Flat risk; HOT at Record price on Chatter. HOT, a leading hotel and leisure company, is frequently mentioned as a private equity break up-recapitalization candidate. HOT is up $1.13 to $70.97. HOT's CEO Steve Heyer resigned on 4/12/07. HOT will announce EPS on 4/26. HOT has a market cap of $16 billion with long term debt of $2.3 billion. HOT reported 2006 annual total revenue of $5.9 billion. HOT May option implied volatility of 26 is near its 26-week average according to Track Data, suggesting non-directional risk.

Option volume leaders today are: Best Buy (NYSE: BBY), Qualcomm (NASDAQ: QCOM), Apple Inc. (NASDAQ: AAPL) and Altria (NYSE: MO).

Daily Option Update is provided by Stock Options Specialist Paul Foster of theflyonthewall.com.